LAVA Therapeutics Future Growth
Future criteria checks 0/6
LAVA Therapeutics's revenue is forecast to decline at 91% per annum while its annual earnings are expected to grow at 1% per year. EPS is expected to grow by 30.2% per annum.
Key information
1.0%
Earnings growth rate
30.2%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | -91.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 31 Mar 2025 |
Recent future growth updates
Recent updates
Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues
Apr 06
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive
Jun 02LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?
Mar 01LAVA Therapeutics: Assessing A Promising Innovator
Oct 18LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M
Sep 13Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | N/A | -37 | -42 | N/A | 3 |
| 12/31/2026 | N/A | -38 | -41 | N/A | 4 |
| 12/31/2025 | N/A | -41 | -32 | N/A | 4 |
| 12/31/2024 | 12 | -25 | -20 | -20 | N/A |
| 9/30/2024 | 7 | -28 | -29 | -29 | N/A |
| 6/30/2024 | 7 | -24 | -27 | -27 | N/A |
| 3/31/2024 | 13 | -29 | -32 | -32 | N/A |
| 12/31/2023 | 7 | -42 | -41 | -40 | N/A |
| 9/30/2023 | 9 | -50 | 6 | 7 | N/A |
| 6/30/2023 | 24 | -41 | -1 | 0 | N/A |
| 3/31/2023 | 20 | -36 | 3 | 3 | N/A |
| 12/31/2022 | 19 | -32 | 3 | 4 | N/A |
| 9/30/2022 | 18 | -25 | -40 | -39 | N/A |
| 6/30/2022 | 5 | -33 | -34 | -33 | N/A |
| 3/31/2022 | 5 | -32 | -33 | -32 | N/A |
| 12/31/2021 | 5 | -42 | -29 | -29 | N/A |
| 9/30/2021 | 6 | -37 | -29 | -28 | N/A |
| 6/30/2021 | 5 | -34 | -25 | -24 | N/A |
| 3/31/2021 | 5 | -31 | -12 | -11 | N/A |
| 12/31/2020 | 4 | -16 | -10 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LVTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LVTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LVTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LVTX is forecast to have no revenue next year.
High Growth Revenue: LVTX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LVTX's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/17 22:39 |
| End of Day Share Price | 2025/04/17 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LAVA Therapeutics N.V. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Reni Benjamin | Citizens JMP Securities, LLC |
| Yu He | H.C. Wainwright & Co. |
| Christopher Howerton | Jefferies LLC |